translocations or amplifications in addition to the genomic alterations presently current in the initial CLL, but deficiency the popular mutations noticed in Principal DLBCL indicating which they may possibly correspond to a unique biological class.gene in patients relapsing following cure Using the BCL2 antagonist venetoclax. 66 Resistance to thes